RESUMEN
BACKGROUND: Recalcitrant dermatophyte infections are being reported from various parts of the world due to varied causes including strain variation, steroid misuse, SQLE mutations, and variable quality of itraconazole pellet formulations. The oral drug preferred in endemic areas is itraconazole, to which MIC levels remain low, and clinical failures to itraconazole reported defy a sound scientific explanation. OBJECTIVES: The objective of the study was to conduct a proteomic and genomic analysis on isolates from therapeutically recalcitrant case with isolation of gene mutations and enzymatic abnormalities to explain azole failures. METHODS: Trichophyton mentagrophyte interdigitale complex strains were isolated from seven clinically non-responding tinea corporis/cruris patients, who had failed a sequential course of 6 weeks of terbinafine 250 mg QD and itraconazole 100 mg BID. After AFST 1 strain, KA01 with high MIC to most drugs was characterized using whole genome sequencing, comparative proteomic profiling, and total sterol quantification. RESULTS: Sterol quantification showed that the standard strain of Trichophyton mentagrophytes (MTCC-7687) had half the ergosterol content than the resistant KA01 strain. Genomic analysis revealed mutations in SQLE, ERG4, ERG11, MDR1, MFS genes, and a novel ERG3 mutation. Proteomic analysis established the aberrant expression of acetyl Co-A transferase in the resistant strain and upregulation of thioredoxin reductase and peroxiredoxin. CONCLUSION: Our findings demonstrate possible reasons for multidrug resistance in the prevalent strain with mutations in genes that predict terbinafine (SQLE) and azole actions (ERG4, ERG11, ERG3) apart from efflux pumps (MDR1, MFS) that can explain multidrug clinical failures.
Asunto(s)
Antifúngicos , Tiña , Humanos , Terbinafina/uso terapéutico , Antifúngicos/uso terapéutico , Antifúngicos/farmacología , Itraconazol/uso terapéutico , Proteómica , Trichophyton/genética , Tiña/tratamiento farmacológico , Tiña/epidemiología , Mutación , Farmacorresistencia Fúngica/genética , Pruebas de Sensibilidad Microbiana , Regulador Transcripcional ERG/genéticaRESUMEN
Small molecule modulators of mitochondrial function have been attracted much attention in recent years due to their potential therapeutic applications for neurodegenerative diseases. The mitochondrial translocator protein (TSPO) is a promising target for such compounds, given its involvement in the formation of the mitochondrial permeability transition pore in response to mitochondrial stress. In this study, we performed a ligand-based pharmacophore design and virtual screening, and identified a potent hit compound, 7 (VH34) as a TSPO ligand. After validating its biological activity against amyloid-ß (Aß) induced mitochondrial dysfunction and in acute and transgenic Alzheimer's disease (AD) model mice, we developed a library of analogs, and we found two most active compounds, 31 and 44, which restored the mitochondrial membrane potential, ATP production, and cell viability under Aß-induced mitochondrial toxicity. These compounds recovered learning and memory function in acute AD model mice with improved pharmacokinetic properties.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Mitocondrias/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Agregación Patológica de Proteínas/tratamiento farmacológico , Bibliotecas de Moléculas Pequeñas/farmacología , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/antagonistas & inhibidores , Péptidos beta-Amiloides/metabolismo , Animales , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Ligandos , Ratones , Mitocondrias/metabolismo , Estructura Molecular , Fármacos Neuroprotectores/síntesis química , Fármacos Neuroprotectores/química , Agregación Patológica de Proteínas/metabolismo , Agregación Patológica de Proteínas/patología , Bibliotecas de Moléculas Pequeñas/síntesis química , Bibliotecas de Moléculas Pequeñas/química , Regulador Transcripcional ERG/antagonistas & inhibidores , Regulador Transcripcional ERG/metabolismoRESUMEN
KvLQT1 and hERG are the α-subunits of the voltage-gated K+ channels which carry the cardiac repolarizing currents IKs and IKr, respectively. These currents function in vivo with some redundancy to maintain appropriate action potential durations (APDs) in cardiomyocytes. As such, protein-protein interactions between hERG and KvLQT1 may be important in normal cardiac electrophysiology, as well as in arrhythmia and sudden cardiac death. Previous phenomenological observations of functional, mutual downregulation between these complementary repolarizing currents in transgenic rabbit models and human cell culture motivate our investigations into protein-protein interactions between hERG and KvLQT1. Previous data suggest that a dynamic, physical interaction between hERG and KvLQT1 modulates the respective currents. However, the mechanism by which hERG-KvLQT1 interactions are regulated is still poorly understood. Phosphorylation is proposed to play a role since modifying the phosphorylation state of each protein has been shown to alter channel kinetics, and both hERG and KvLQT1 are targets of the Ser/Thr protein kinase PKA, activated by elevated intracellular cAMP. In this work, quantitative apFRET analyses of phosphonull and phosphomimetic hERG and KvLQT1 mutants indicate that unphosphorylated hERG does not interact with KvLQT1, suggesting that hERG phosphorylation is important for wild-type proteins to interact. For proteins already potentially interacting, phosphorylation of KvLQT1 appears to be the driving factor abrogating hERG-KvLQT1 interaction. This work increases our knowledge about hERG-KvLQT1 interactions, which may contribute to the efforts to elucidate mechanisms that underlie many types of arrhythmias, and also further characterizes novel protein-protein interactions between two distinct potassium channel families.
Asunto(s)
Arritmias Cardíacas/metabolismo , Canal de Potasio ERG1/metabolismo , Canal de Potasio KCNQ1/metabolismo , Arritmias Cardíacas/genética , Proteínas Quinasas Dependientes de AMP Cíclico/genética , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Canal de Potasio ERG1/genética , Células HEK293 , Humanos , Canal de Potasio KCNQ1/genética , Fosforilación/genética , Regulador Transcripcional ERG/genética , Regulador Transcripcional ERG/metabolismoRESUMEN
Nux vomica has been effectively used in Traditional Chinese Medicine. The processing of Nux vomica is necessary to reduce toxicity before it can be used in clinical practice. However, the mechanism for processing detoxification is unclear. hERG channels have been subjected to a routine test for compound cardiac toxicity in the drug development process. Therefore, we examined the effects and mechanisms of strychnine and brucine, two main ingredients of Nux vomica, and their N-oxides on hERG channels. Strychnine and brucine exhibited concentration-dependent inhibition of hERG channels with IC50 values of 25.9⯵M and 44.18⯵M, respectively. However, their nitrogen oxidative derivatives produced by processing of Nux vomica, strychnine N-oxide and brucine N-oxide, lost their activity on hERG channels. Compared to their parent compounds, only an oxygen atom was introduced in the nitrogen oxidative isoforms to compensate for the N+â¯-â¯charge, suggesting that the protonated nitrogen is the key group for strychnine and brucine binding to hERG channel. Alanine-mutagenesis identified Y652 is the most important residue for strychnine and brucine binding to hERG channel. Y652A mutation increased the IC50 for strychnine and brucine by 21.64-fold and 29.78-fold that of WT IhERG, respectively. Docking simulations suggested that the protonated nitrogen of strychnine and brucine formed a cation-π interaction with the aromatic ring of Y652. This study suggests that introduction of an oxygen to compensate for the N+â¯-â¯charge could be a useful strategy for reducing hERG potency and increasing the safety margin of alkaloid-type compounds in drug development.
Asunto(s)
Oxígeno/metabolismo , Canales de Potasio/metabolismo , Estricnina/análogos & derivados , Estricnina/metabolismo , Alcaloides/metabolismo , Línea Celular , Células HEK293 , Humanos , Medicina Tradicional China/métodos , Nitrógeno/metabolismo , Sodio/metabolismo , Relación Estructura-Actividad , Strychnos nux-vomica/química , Regulador Transcripcional ERG/metabolismoRESUMEN
In this study, we catalog structure activity relationships (SAR) of several short chain fatty acid (SCFA)-modified hexosamine analogues used in metabolic glycoengineering (MGE) by comparing in silico and experimental measurements of physiochemical properties important in drug design. We then describe the impact of these compounds on selected biological parameters that influence the pharmacological properties and safety of drug candidates by monitoring P-glycoprotein (Pgp) efflux, inhibition of cytochrome P450 3A4 (CYP3A4), hERG channel inhibition, and cardiomyocyte cytotoxicity. These parameters are influenced by length of the SCFAs (e.g., acetate vs n-butyrate), which are added to MGE analogues to increase the efficiency of cellular uptake, the regioisomeric arrangement of the SCFAs on the core sugar, the structure of the core sugar itself, and by the type of N-acyl modification (e.g., N-acetyl vs N-azido). By cataloging the influence of these SAR on pharmacological properties of MGE analogues, this study outlines design considerations for tuning the pharmacological, physiochemical, and the toxicological parameters of this emerging class of small molecule drug candidates.
Asunto(s)
Inhibidores del Citocromo P-450 CYP3A/farmacología , Diseño de Fármacos , Ácidos Grasos Volátiles/farmacología , Hexosaminas/farmacología , Ingeniería Metabólica/métodos , Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Animales , Animales Recién Nacidos , Células Cultivadas , Citocromo P-450 CYP3A/metabolismo , Inhibidores del Citocromo P-450 CYP3A/química , Evaluación Preclínica de Medicamentos , Ácidos Grasos Volátiles/química , Hexosaminas/química , Estructura Molecular , Miocitos Cardíacos/efectos de los fármacos , Cultivo Primario de Células , Ratas , Relación Estructura-Actividad , Pruebas de Toxicidad/métodos , Regulador Transcripcional ERG/antagonistas & inhibidoresRESUMEN
Combination studies of neurokinin 1 (NK1) receptor antagonists and serotonin-selective reuptake inhibitors (SSRIs) have shown promise in preclinical models of depression. Such a combination may offer important advantages over the current standard of care. Herein we describe the discovery and optimization of an indazole-based chemotype to provide a series of potent dual NK1 receptor antagonists/serotonin transporter (SERT) inhibitors to overcome issues of ion channel blockade. This effort culminated in the identification of compound 9, an analogue that demonstrated favorable oral bioavailability, excellent brain uptake, and robust in vivo efficacy in a validated depression model. Over the course of this work, a novel heterocycle-directed asymmetric hydrogenation was developed to facilitate installation of the key stereogenic center.
Asunto(s)
Antidepresivos/farmacología , Indazoles/farmacología , Antagonistas del Receptor de Neuroquinina-1/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Administración Oral , Animales , Antidepresivos/síntesis química , Antidepresivos/química , Antidepresivos/toxicidad , Trastorno Depresivo/tratamiento farmacológico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Gerbillinae , Humanos , Indazoles/síntesis química , Indazoles/química , Indazoles/toxicidad , Ratones , Estructura Molecular , Antagonistas del Receptor de Neuroquinina-1/síntesis química , Antagonistas del Receptor de Neuroquinina-1/química , Antagonistas del Receptor de Neuroquinina-1/toxicidad , Ratas , Receptores de Neuroquinina-1/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Inhibidores Selectivos de la Recaptación de Serotonina/química , Inhibidores Selectivos de la Recaptación de Serotonina/toxicidad , Relación Estructura-Actividad , Regulador Transcripcional ERG/metabolismoRESUMEN
BACKGROUND: Gleason Score (GS) upgrading is generally considered a trigger for exit to definitive treatment during active surveillance (AS). Predicting the potential for GS upgrading would be of value in assessing AS eligibility. METHODS: We assessed the performance of biomarkers in presurgical specimens of expressed prostatic secretion (EPS) in this setting. RESULTS: Although EPS volume, total recovered RNA, and RNA expression biomarkers (TMPRSS2: ERG, PCA3, PSA) have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients, they were unable to predict upgrading in patients eligible for active surveillance under National Comprehensive Cancer Network guidelines. CONCLUSIONS: These biomarkers do not improve the prediction of upgrading over indications from standard clinical parameters. IMPACT: Additional biomarkers will be needed in this area. Cancer Epidemiol Biomarkers Prev; 25(12); 1643-5. ©2016 AACR.
Asunto(s)
Clasificación del Tumor/métodos , Neoplasias de la Próstata/diagnóstico , Antígenos de Neoplasias/genética , Biomarcadores de Tumor/genética , Expresión Génica , Humanos , Masculino , Pronóstico , Antígeno Prostático Específico/genética , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , Sensibilidad y Especificidad , Serina Endopeptidasas/genética , Regulador Transcripcional ERG/genéticaRESUMEN
BACKGROUND: There is limited evidence that supports etiologically distinct molecular subtypes of prostate cancer, the identification of which may improve prevention. Given their antioxidant properties, we hypothesized that lycopene and tomato sauce may be especially protective against diseases harboring the common gene fusion transmembrane protease, serine 2 (TMPRSS2):v-ets avian erythroblastosis virus E26 oncogene homolog (ERG). OBJECTIVE: We aimed to examine associations between estimated lycopene and tomato sauce intake and the risk of prostate cancer defined by ERG protein expression subtype. DESIGN: Our study population consisted of a prospective cohort of 46,719 men from the Health Professionals Follow-Up Study. TMPRSS2:ERG was assessed by ERG immunohistochemistry on tumor tissue microarrays constructed from radical prostatectomy specimens. We used multivariable competing risk models to calculate HRs and 95% CIs for the risk of ERG-positive and, separately, ERG-negative disease. We implemented inverse probability weighting to account for evaluating ERG status only in surgically treated cases. RESULTS: During 23 y of follow-up, 5543 men were diagnosed with prostate cancer, among whom 884 were assayed for ERG (426 ERG-positive). With inclusion of only the latter cases, increasing cumulative average tomato sauce intake was associated with a decreased risk of prostate cancer overall (≥2 servings/wk compared with <1 serving/mo; multivariable HR: 0.70; 95% CI: 0.52, 0.95; P-trend = 0.002). With respect to molecular subtypes, cumulative average tomato sauce intake was associated with a decreased risk of ERG-positive disease (HR: 0.54; 95% CI: 0.37, 0.81; P-trend = 0.004) but not with ERG-negative disease (HR: 0.96; 95% CI: 0.62, 1.50; P-trend = 0.10) (P-heterogeneity = 0.04). Increasing quintiles of lycopene intake were associated with a decreased risk of both subtypes (P-heterogeneity = 0.79). Inverse probability weighting did not materially change the results. CONCLUSIONS: Our results lend some support to the hypothesis that prostate cancers that harbor TMPRSS2:ERG may be etiologically distinct from fusion-negative cancers. In particular, tomato sauce consumption may play a role in reducing TMPRSS2:ERG-positive disease.
Asunto(s)
Antioxidantes/uso terapéutico , Carotenoides/uso terapéutico , Dieta , Proteínas de Fusión Oncogénica/metabolismo , Neoplasias de la Próstata/prevención & control , Solanum lycopersicum/química , Transactivadores/metabolismo , Adulto , Antineoplásicos Fitogénicos/uso terapéutico , Conducta Alimentaria , Humanos , Licopeno , Masculino , Persona de Mediana Edad , Extractos Vegetales/uso terapéutico , Neoplasias de la Próstata/metabolismo , Regulador Transcripcional ERGRESUMEN
ERG and androgen receptor (AR) are known to function cooperatively in prostate cancer (PCa) progression. However, the prognostic value of combined ERG and AR expression and potential pathways are not well characterized. We assessed ERG and AR protein expression by immunohistochemistry in a cohort of 312 men with PCa diagnosed by transurethral resection of the prostate (TURP). Patients were divided into those with no prior hormonal treatment (designated as PCa/AdvPCa) vs. those with castrate-resistant PCa (CRPC) undergoing channel TURP to relieve obstructive symptoms. The expression status was correlated with various clinical-pathological parameters. The Swedish watchful-waiting cohort was used for validation and characterization of potential gene signatures associated with ERG and AR. Patients with combined ERG-positive/AR high expression profile demonstrated higher rates of PCa-specific mortality (PCSM) compared with patients with ERG-negative/AR low in patients with no prior treatment (n = 90, P = 0.032), but this was attenuated in the overall cohort which included the CRPC subgroup (n = 125, P = 0.096). The prognostic significance to PCSM was validated in the Swedish watchful waiting cohort in univariate (HR: 3.3; 95% CI: 1.9-5.6, P = 4.25E-5) and multivariate analysis (HR: 2; 95% CI: 0.97-4.1, P = 0.057), which included Gleason score. ERG/AR overexpression status characterized 152 genes signatures including WNT, PI3K/AKT and chemokine signaling pathways known to be deregulated in PCa. In conclusion, combined ERG/AR overexpression signifies a class of patients at highest-risk of PCSM with specific key genetic alteration likely responsible for disease progression. The prognostic value of combined ERG/AR overexpression and its associated genes should be further investigated as potential prognostic and therapeutic targets in prostate cancer progression.
Asunto(s)
Andrógenos/deficiencia , Neoplasias de la Próstata/diagnóstico , Receptores Androgénicos/metabolismo , Transactivadores/metabolismo , Anciano , Anciano de 80 o más Años , Quimiocinas/metabolismo , Estudios de Cohortes , Terapia Combinada , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Hormona Liberadora de Gonadotropina/agonistas , Humanos , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Antígeno Prostático Específico/metabolismo , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/terapia , Neoplasias de la Próstata Resistentes a la Castración/diagnóstico , Neoplasias de la Próstata Resistentes a la Castración/metabolismo , Neoplasias de la Próstata Resistentes a la Castración/mortalidad , Neoplasias de la Próstata Resistentes a la Castración/terapia , Proteínas Proto-Oncogénicas c-akt/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptores Androgénicos/genética , Transducción de Señal , Transactivadores/genética , Regulador Transcripcional ERG , Resección Transuretral de la Próstata , Espera Vigilante , Proteínas Wnt/genética , Proteínas Wnt/metabolismoRESUMEN
Several in vivo and in vitro studies have assessed methods of evaluating the cardio toxicity of compounds during drug development due to its importance for predicting human toxicity. However, in vivo/in vitro relationships have not yet been reported using a zebrafish model. This study determined the bradycardia of 15 compounds by evaluating the change in heart beat rate (HBR) in zebrafish, hERG fluorescence polarization (hERG-FP), and ionic current change using a patch clamp (hERG-PC). In addition, a model for prediction of drug-induced bradycardia was established using in vivo and in vitro assays designed for high-throughput toxicological screening. The IC(50) values correlated well in two in vitro studies (R(2)=0.9). The change in HBR in zebrafish caused by the compounds could be estimated using the IC(50) from the hERG-FP assay [(i.e., % of HBR=19.5×log(IC(50), hERG-FP)] or hERG-PC assay [(i.e., % of HBR=19.6×log(IC(50), hERG-FP)]. To validate the predictive model, 10 unknown compounds were used and the percentages of the HBR were estimated using the model. The observed and predicted HBR% for the compounds in zebrafish were well-correlated (R(2)=0.948). Therefore, the proposed models were useful for prediction of drug-induced bradycardia related cardio toxicity.
Asunto(s)
Bradicardia/inducido químicamente , Evaluación Preclínica de Medicamentos/métodos , Farmacología/métodos , Animales , Productos Biológicos , Relación Dosis-Respuesta a Droga , Polarización de Fluorescencia , Células HEK293 , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Técnicas de Placa-Clamp , Valor Predictivo de las Pruebas , Transactivadores/antagonistas & inhibidores , Regulador Transcripcional ERG , Pez CebraRESUMEN
Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl-amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.
Asunto(s)
Amidinas/farmacología , Antineoplásicos/farmacología , Tiofenos/farmacología , Transactivadores/antagonistas & inhibidores , Activación Transcripcional/efectos de los fármacos , Amidinas/química , Amidinas/metabolismo , Antineoplásicos/química , Antineoplásicos/metabolismo , Sitios de Unión , Línea Celular Tumoral , ADN/química , ADN/metabolismo , Evaluación Preclínica de Medicamentos , Humanos , Tiofenos/química , Tiofenos/metabolismo , Transactivadores/metabolismo , Regulador Transcripcional ERGRESUMEN
To assess the incidence of ERG rearrangements and PTEN deletions in a group of prognostically favorable PCA tumors of the transition zone (TZ). We interrogated 54 unsuspected PCA tumors using fluorescence in-situ hybridization for ERG rearrangements and PTEN deletions. ERG rearrangements were detected in 6/47 (12.7%) cases with 4/6 (66%) occurring by deletion. PTEN deletions were detected in 9/47 (19.1%) cases with only 3/47 (6.4%) having both PTEN losses and ERG rearrangements (p = 0.07). Only ERG rearrangements were associated with higher tumor volume > 5% (p = 0.04); PTEN deletions showed similar trends (p = 0.06). None of the markers showed association with Gleason score. In conclusion, although TZ and peripheral zone tumors share similar molecular etiologies, they exhibit differences in the rates of ERG and PTEN aberrations. The differences of ERG and /or PTEN genetic aberrations in TZ tumors may point toward a subset of tumors with adverse behavior. Additional studies implementing ERG and PTEN tissue-based FISH assays in tumors of the TZ are warranted to substantiate the potential clinical value of these biomarkers in the management of men with incidental PCA.
Asunto(s)
Biomarcadores de Tumor/genética , Aberraciones Cromosómicas , Fosfohidrolasa PTEN/genética , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Transactivadores/genética , Anciano , Anciano de 80 o más Años , Humanos , Hibridación Fluorescente in Situ , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata/cirugía , Eliminación de Secuencia/genética , Regulador Transcripcional ERG , Resección Transuretral de la PróstataRESUMEN
Specialised brain structures allow songbirds to process acoustic signals. One of these brain areas, the NCM (caudomedial neostriatum), shows an immediate-early gene ZENK response when a bird hears a conspecific song. Using a neuro-ethological approach, we investigate if high level of background noise added to conspecific song can modify this song-induced genic activation. We test the ZENK activation in the NCM of adult male Zebra finches Taeniopygya guttata (n = 17) by playing back conspecific signals mixed with different levels of noise, the successful discrimination being reflected by the birds' (n = 6) behavioural responses to these stimuli. From our results, it appears that a high genic activation of the NCM does not necessarily require the audition of an undegraded species-specific signal. Nevertheless, it requires that the signal still contains sufficient information to elicit a behavioural response. The genic activation of the NCM remains thus stable against very high levels of a wide-band background noise, as far as the signal recognition remains possible for the bird.
Asunto(s)
Estimulación Acústica/métodos , Encéfalo/efectos de la radiación , Regulación de la Expresión Génica/efectos de la radiación , Ruido , Animales , Conducta Animal , Encéfalo/metabolismo , Recuento de Células/métodos , Proteínas de Unión al ADN/metabolismo , Relación Dosis-Respuesta en la Radiación , Genes Inmediatos-Precoces/fisiología , Genes Inmediatos-Precoces/efectos de la radiación , Inmunohistoquímica/métodos , Masculino , Actividad Motora/efectos de la radiación , Tiempo de Reacción/efectos de la radiación , Pájaros Cantores , Transactivadores/metabolismo , Regulador Transcripcional ERG , Vocalización Animal/fisiologíaRESUMEN
OBJECTIVES: We sought to determine whether oral potassium supplementation safely increases serum K(+) and results in sustained improvement of repolarization parameters in long QT syndrome type 2 (LQT2) subjects. BACKGROUND: Mutations in HERG (LQT2), the gene encoding the rapid delayed rectifier K(+) current I(Kr), account for a significant proportion of congenital long QT syndrome (LQTS). The magnitude of I(Kr) is paradoxically increased by an increase in extracellular K(+). We tested the hypothesis that long-term oral potassium supplementation results in a mild, sustainable increase in serum K(+) that improves repolarization abnormalities in subjects with LQT2. METHODS: After an initial evaluation consisting of electrocardiography, electrolytes, blood urea nitrogen, and creatinine, escalating doses of potassium chloride (KCl) and spironolactone were administered to eight subjects with six distinct HERG mutations. Medications were continued for four weeks, at which time, the final evaluation was undertaken. Beta-adrenergic blocking therapy was maintained. RESULTS: The subjects ranged in age from 11 to 52 years. The average daily KCl and spironolactone dose was 3.3 +/- 1.5 mEq/kg and 3.5 +/- 1.2 mg/kg, respectively, and this regimen resulted in an increase in serum K(+) from 4.0 +/- 0.3 to 5.2 +/- 0.3 mEq/l. There were no serious complications associated with therapy. The increase in serum K(+) resulted in a decrease in the corrected QT interval from 526 +/- 94 to 423 +/- 36 ms (mean +/- SD; lead V(2)). Both QT dispersion and T-wave morphology improved in most subjects. CONCLUSIONS: Long-term oral potassium administration increases serum K(+) in patients with LQT2. This can be achieved safely and results in improvement in repolarization. Further studies are warranted to determine whether this will reduce the incidence of life-threatening events in LQTS patients.
Asunto(s)
Proteínas de Transporte de Catión , Proteínas de Unión al ADN , Corazón/fisiología , Síndrome de QT Prolongado/tratamiento farmacológico , Síndrome de QT Prolongado/genética , Canales de Potasio con Entrada de Voltaje , Cloruro de Potasio/administración & dosificación , Compuestos de Potasio/administración & dosificación , Transactivadores , Administración Oral , Adolescente , Adulto , Niño , Suplementos Dietéticos , Diuréticos/administración & dosificación , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go , Femenino , Humanos , Masculino , Persona de Mediana Edad , Canales de Potasio/genética , Espironolactona/administración & dosificación , Regulador Transcripcional ERG , Resultado del TratamientoRESUMEN
Based on similarity of electrocardiographic features, bidirectional ventricular tachycardia has been considered a variant of long QT syndrome. Genes causing long QT syndrome were used as candidate genes in 4 patients with bidirectional ventricular tachycardia. In 2 patients, we identified a common low penetrance HERG allele (R1047L) with an intermediate biophysical phenotype.
Asunto(s)
Proteínas de Transporte de Catión , Proteínas de Unión al ADN , Síndrome de QT Prolongado/genética , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/genética , Taquicardia Ventricular/genética , Transactivadores , Adolescente , Alelos , Preescolar , Canal de Potasio ERG1 , Técnicas Electrofisiológicas Cardíacas , Canales de Potasio Éter-A-Go-Go , Femenino , Humanos , Masculino , Fenotipo , Canales de Sodio/genética , Regulador Transcripcional ERGRESUMEN
By way of example, we discuss the apparent 'failure' of in silico ADME/Tox models and attempt to understand the causes. Often, the interpretation of the success of models lies in their use and the expectations of the user. Other times, models are, in fact, of little value. Disappointing results can be linked to the key aspects of the model and modeling procedure, many of these related to the original data and its interpretation. We make recommendations to providers of models regarding the development, description, and use of models as well as the data and information that are important to understanding a model's quality and scope of use.
Asunto(s)
Proteínas de Transporte de Catión , Simulación por Computador , Diseño Asistido por Computadora , Proteínas de Unión al ADN , Diseño de Fármacos , Modelos Biológicos , Farmacocinética , Canales de Potasio con Entrada de Voltaje , Transactivadores , Proteínas Portadoras/metabolismo , Permeabilidad de la Membrana Celular , Células Cultivadas/efectos de los fármacos , Neoplasias del Colon/patología , Diseño Asistido por Computadora/normas , Inhibidores del Citocromo P-450 CYP2D6 , Evaluación Preclínica de Medicamentos , Canal de Potasio ERG1 , Inhibidores Enzimáticos/farmacología , Canales de Potasio Éter-A-Go-Go , Humanos , Modelos Lineales , Técnicas de Placa-Clamp , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio/efectos de los fármacos , Solubilidad , Regulador Transcripcional ERGRESUMEN
A data set consisting of twenty-two sertindole analogues and ten structurally diverse inhibitors, spanning a wide range in potency, was analyzed using CoMSiA. A homology model of HERG was constructed from the crystal structure of the open MthK potassium channel. A complementary relationship between our CoMSiA and homology models is apparent when the long inhibitor axis is oriented parallel to the longitudinal axis of the pore, with the tail region pointed toward the selectivity filter. The key elements of the pharmacophore, the CoMSiA and the homology model are: (1) The hydrophobic feature optimally consists of an aromatic group that is capable of engaging in pi-stacking with a Phe656 side chain. Optionally, a second aromatic or hydrophobic group present in some inhibitors may contact an additional Phe656 side chain. (2) The basic nitrogen appears to undergo a pi-cation interaction with Tyr652. (3) The pore diameter (12A+), and depth of the selectivity loop relative to the intracellular opening, act as constraints on the conformation-dependent inhibitor dimensions.
Asunto(s)
Proteínas de Transporte de Catión , Proteínas de Unión al ADN , Bloqueadores de los Canales de Potasio/síntesis química , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/química , Relación Estructura-Actividad Cuantitativa , Homología Estructural de Proteína , Transactivadores , Aminoácidos Aromáticos , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Imidazoles/síntesis química , Imidazoles/farmacología , Indoles/síntesis química , Indoles/farmacología , Concentración 50 Inhibidora , Modelos Moleculares , Bloqueadores de los Canales de Potasio/química , Bloqueadores de los Canales de Potasio/farmacología , Unión Proteica , Conformación Proteica , Relación Estructura-Actividad , Regulador Transcripcional ERGRESUMEN
Peptide toxins with disulfide-stabilized structures have been used as molecular calipers to probe the outer vestibule structure of K channels. We want to apply this approach to the human ether-a-go-go-related gene (HERG) channel, whose outer vestibule is unique in structure and function among voltage-gated K channels. Our focus here is BeKm-1, a HERG-specific peptide toxin that can suppress HERG in the low nM concentration range. Although BeKm-1 shares the three-dimensional scaffold with the well-studied charybdotoxin, the two use different mechanisms in suppressing currents through their target K channels. BeKm-1 binds near, but not inside, the HERG pore, and it is possible that BeKm-1-bound HERG channels can conduct currents although with markedly altered voltage-dependence and kinetics of gating. BeKm-1 and ErgTx1 differ in three-dimensional scaffold, but the two share mechanism of action and have overlapping binding sites on the HERG channel. For both, residues in the middle of the S5-P linker (the putative 583-597 helix) and residues at the pore entrance are critical for binding, although specific contact points vary between the two. Toxin foot printing using BeKm-1 and ErgTx1 will likely provide complementary information about the unique outer vestibule structure of the HERG channel.
Asunto(s)
Proteínas de Transporte de Catión , Caribdotoxina/química , Proteínas de Unión al ADN , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/química , Canales de Potasio/fisiología , Venenos de Escorpión/química , Venenos de Escorpión/farmacología , Transactivadores , Secuencia de Aminoácidos , Animales , Sitios de Unión , Células Cultivadas , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go , Humanos , Activación del Canal Iónico/efectos de los fármacos , Activación del Canal Iónico/fisiología , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/fisiología , Datos de Secuencia Molecular , Oocitos/efectos de los fármacos , Oocitos/fisiología , Porosidad , Canales de Potasio/efectos de los fármacos , Unión Proteica , Conformación Proteica , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Relación Estructura-Actividad , Regulador Transcripcional ERG , Xenopus laevisRESUMEN
The KCNE genes encode small, single transmembrane domain peptides that associate with pore-forming potassium channel subunits to form mixed complexes with unique characteristics. We have identified a novel member of the human KCNE gene family, hKCNE4. The hKCNE4 gene encodes 170 amino acid protein and is localized to chromosome 2q35-36. The protein sequence shows 90% homology to mouse KCNE4 and 38% identity to human KCNE1. Northern blot analysis revealed that hKCNE4 is expressed strongly in heart, skeletal muscle, and kidney, less in placenta, lung, and liver, and weakly in brain and blood cells. Electrophysiological study showed that hKCNE4 modulates the activation of the KCNQ1 channel.